Literature DB >> 2543422

Anti-inflammatory drugs in experimental atherosclerosis. 7. Spontaneous atherosclerosis in WHHL rabbits and inhibition by cortisone acetate.

A N Makheja1, S Bloom, R Muesing, T Simon, J M Bailey.   

Abstract

The Watanabe heritable hyperlipidemic (WHHL) rabbit, an animal model for familial hypercholesterolemia, has a deficiency in low density lipoprotein (LDL) receptor binding and exhibits elevated plasma lipoprotein levels and spontaneous atherosclerosis. Since atherosclerotic plaque formation has a number of features in common with the inflammatory process, we have investigated the effect of dietary supplementation with an anti-inflammatory steroid (cortisone acetate, 5 mg daily for 3 months) on atherosclerosis using the WHHL rabbit as a model. Atherosclerotic plaque formation in cortisone-fed animals was reduced by about 60% compared to control WHHL rabbits. Steroid administration increased circulating cholesterol levels modestly and triglycerides were increased about 6-fold. While very low density lipoprotein (VLDL)-cholesterol was increased, LDL-cholesterol levels were decreased and the particle was more triglyceride-enriched as well as less dense. Steroid-fed animals also exhibited decreased platelet aggregation and increased aortic 15-lipoxygenase activity. The histological observations showed typical fibrous plaques in aortas of both control and cortisone-fed rabbits, with intima thickened by foamy macrophages and subcellular lipoproteinaceous debris covered by a fibrous cap. These findings thus indicate that steroids reduce the rate of plaque initiation or progression but do not significantly change the histological appearance of the lesion.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2543422     DOI: 10.1016/0021-9150(89)90099-3

Source DB:  PubMed          Journal:  Atherosclerosis        ISSN: 0021-9150            Impact factor:   5.162


  16 in total

1.  Glucocorticoid treatment and cardiovascular disease.

Authors:  M K C Ng; D S Celermajer
Journal:  Heart       Date:  2004-08       Impact factor: 5.994

Review 2.  Atherosclerosis: inhibition of regression as therapeutic possibilities.

Authors:  M J Davies; D M Krikler; D Katz
Journal:  Br Heart J       Date:  1991-06

3.  A festschrift for J. Martyn Bailey, a biochemist extraordinaire.

Authors:  Timothy Hla; Steven J Feinmark
Journal:  Prostaglandins Other Lipid Mediat       Date:  2006-12-27       Impact factor: 3.072

Review 4.  Emerging cellular functions of the lipid metabolizing enzyme 15-Lipoxygenase-1.

Authors:  Melis Çolakoğlu; Sinem Tunçer; Sreeparna Banerjee
Journal:  Cell Prolif       Date:  2018-07-30       Impact factor: 6.831

Review 5.  Atherosclerosis: the eicosanoid connection.

Authors:  A N Makheja
Journal:  Mol Cell Biochem       Date:  1992-04       Impact factor: 3.396

Review 6.  Therapeutic manipulation of glucocorticoid metabolism in cardiovascular disease.

Authors:  Patrick W F Hadoke; Javaid Iqbal; Brian R Walker
Journal:  Br J Pharmacol       Date:  2009-02-23       Impact factor: 8.739

Review 7.  Lipoproteins and lipoprotein mimetics for imaging and drug delivery.

Authors:  C Shad Thaxton; Jonathan S Rink; Pratap C Naha; David P Cormode
Journal:  Adv Drug Deliv Rev       Date:  2016-04-29       Impact factor: 15.470

8.  Overexpression of human 15(S)-lipoxygenase-1 in RAW macrophages leads to increased cholesterol mobilization and reverse cholesterol transport.

Authors:  Ginny L Weibel; Michelle R Joshi; Eric T Alexander; Peijuan Zhu; Ian A Blair; George H Rothblat
Journal:  Arterioscler Thromb Vasc Biol       Date:  2009-03-26       Impact factor: 8.311

9.  Interleukin 1 regulates heparin-binding growth factor 2 gene expression in vascular smooth muscle cells.

Authors:  C G Gay; J A Winkles
Journal:  Proc Natl Acad Sci U S A       Date:  1991-01-01       Impact factor: 11.205

10.  Expression of 5-lipoxygenase and 15-lipoxygenase in rheumatoid arthritis synovium and effects of intraarticular glucocorticoids.

Authors:  Karina Roxana Gheorghe; Marina Korotkova; Anca Irinel Catrina; Linda Backman; Erik af Klint; Hans-Erik Claesson; Olof Rådmark; Per-Johan Jakobsson
Journal:  Arthritis Res Ther       Date:  2009-06-04       Impact factor: 5.156

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.